Is your company trying to get new drugs approved in Brazil? In this article, originally published on Sept. 24, 2020, Redica Systems Senior GMP Quality Expert Jerry Chapman provides insights into the country’s CMC requirements and what they mean for getting drugs approved in this market.

Brazil—the largest country in South America with the sixth largest population in the world—has a population with many unmet medical needs. Conversely, drug companies have experienced some difficulty accessing this market due to country-specific requirements that, in the past, have proven challenging to navigate.

Since becoming a member of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) in 2016, however, Brazil’s regulatory agency, ANVISA, has begun moving toward regulatory harmonization with international norms and standards.

At the FDA/Xavier PharmaLink conference held virtually in March 2020, Merck CMC Director and Senior Scientist Tatiana Gaban—who has led Merck’s CMC Latin America team based in Sao Paulo—provided an in-depth look at the changing CMC regulatory landscape in Brazil. Her talk included a more detailed look at what ANVISA’s membership in ICH means for drug companies hoping to get their products into the Brazilian market.

This is the second part of a three-part story on CMC filing challenges and opportunities in Latin America. Part I provided an overview of the region. Part II focuses specifically on Brazil. Part III provides more detail regarding Mexico, Argentina, Colombia, and Peru.

ANVISA was founded in 1999. Gaban characterizes it as “a complex agency in terms of the amount of documentation that is required from a CMC standpoint.” She also noted that ANVISA is highly active in terms of the volume of draft and final regulations it publishes and that it welcomes discussion and input on draft guidance documents.

“ANVISA has a very clear and established procedure to release draft and final regulations,” Gaban explained. “It is clear how companies can contribute, and how the information and suggestions are evaluated by the regulators is visible.”

Specific Product Registration Requirements

Brazil has specific requirements in its new drug submission process for product stability data and analytical method validation, among others (see Figure 1).

Overview of Brazil CMC Regulations

FIGURE 1 | Overview of CMC Requirements in Brazil

Country-Specific Requirements

Stability studies must be conducted for Zone IVB (hot, higher humidity) with six months of accelerated stability and six months of long-term stability to request a 24-month shelf life. No extrapolation is allowed, and specific studies are expected for each dosage form.

Also, there are specific requirements in terms of analytical validation. While it is becoming aligned with ICH, there are country-specific requirements as well.

Post-registration guidance is also specific with “a huge amount of data and details required that are not aligned with the CTD,” Gaban said.

For large molecules, there is a requirement to provide shipping qualification. ANVISA’s guideline for transport qualification of biological products explains the requirements for validating temperature-control procedures during shipping.

She also noted that ANVISA is highly active in terms of the volume of draft and final regulations it publishes

Average Approval Times

Average approval times are 15 to 18 months for drug products and 24 months for fixed-dose combinations. Variations take six to 14 months. A conditional approval pathway was established through regulation. “It may be granted if ANVISA does not initiate the review within the timelines established by law, after the submission. As a result, timelines have been improving,” Gaban pointed out.

Other Relevant Information

ANVISA became an ICH member in 2016, which means that its guidance must align with ICH over time. However, ANVISA will keep some country-specific requirements. The agency is evaluating the need to establish a balance between what is required at a local level and what is aligned with ICH. In addition, ANVISA has started the process of becoming a Pharmaceutical Inspection Cooperation Scheme (PIC/S) member. For this, it is currently at “Applicant” status.

The Common Technical Document (CTD) format has not been implemented yet, although the local Module 4 guidance is already in place and the agency has indicated that implementation is coming. There is no projected date.

Local release testing is mandatory for small molecules in Brazil. There are some specific guidelines and pathways established for rare diseases and priority submissions as defined by ANVISA.

ICH Implementation Status

ANVISA, like any agency that is approved for ICH membership, must adopt ICH guidelines in a phased approach, with three levels of adoption (see Figure 2).

ICH Implementation Plan for ANVISA

FIGURE 2 | Guidelines for ICH Implementation in Brazil

To be eligible to join, ANVISA needed to revise its stability guidance in line with ICH Q1. In November 2019, it published new requirements for small molecule stability information to be provided in the dossier. There are some meetings occurring within the agency to discuss topics that are potentially not aligned with the ICH.

ANVISA became an ICH member in 2016, which means that its guidance must align with ICH over time

Regarding the status of CTD modules M2 and M4, ANVISA issued a guidance in August 2019. The adoption of the CTD format by applicants will not be mandatory in the beginning. ANVISA plans frequent dialogue with the industry via meetings and events to ensure effective adherence to the new format.

A mandatory adoption deadline will be defined that considers the needs of the industry; companies will also need to implement this guideline internally and the content needs to be harmonized and coordinated to ensure successful implementation. ANVISA plans to adopt the electronic CTD (eCTD) to ensure maximum benefit to CTD format adherence.

ANVISA is a member of the ICH Management Committee, which is the body that oversees operational aspects of ICH on behalf of all members, including administrative and financial matters and oversight of the Working Groups. ANVISA has issued several “calls for contribution” to ICH guidance and ICH review initiatives. This is an important initiative that allows Brazil-specific concerns to be discussed with ICH. A “Call for contributions” has been issued so far for:

  • ICH M10: Bioanalytical Method Validation
  • ICH Q3D (R1): Elemental Impurities
  • ICH M9: Biopharmaceutics Classification System-based Waivers

Part III looks at CMC requirements for Mexico, Argentina, Columbia, and Peru.

Get Your Arms Around the World with Redica Systems

Our regulatory surveillance can help ensure you never miss a signal when it comes to regulatory updates from Brazil. Below are recent regulatory updates from this country:

Resolution of the Collegiate Board – RDC No. 747, of August 19, 2022

Resolution Of The Collegiate Board – RDC No. 742, Of August 10, 2022 on Providing the criteria for conducting relative bioavailability/bioequivalence (BD/BE) studies and pharmacokinetic studies

Brazilian Pharmacopoeia Work Program

Log in to your Redica Systems account to access these regulatory documents. Don’t have a Redica Systems account? Contact us to see how our platform can help your team stay on top of ever-changing regulatory developments around the world.

Additional Global Regulatory Updates

How To Get Products Approved In Asia-Pacific Markets

Navigating Drug Approvals and Post-Approval Changes in the Asia-Pacific Region

An Inside Look at China’s Regulatory and Drug Approval Processes

UK’s MHRA Reinventing Itself as Sovereign Regulator

Comparing and Analyzing Russian, UK, and US Top Ten Pharma Inspection Findings FY 2019

Webinar: Comparing and Analyzing Russian, UK, and US Top Ten Pharma Inspection Findings FY 2019

Presented by Jerry Chapman on October 29, 2020

What you will learn:

  • A comparison of 483 observations in FY2019
  • Top 10 Russian Ministry of Health inspection findings
  • Top 10 FDA Warning Letter findings
  • Top MHRA inspection findings
Redica Systems Enforcement Analytics

Get help choosing the right CRO.

Enter your email address and someone will contact you shortly to customize your insights.

Experience the Power of Redica Systems

Complete the form and one of our experts will reach out to you to schedule a demo and answer questions about our subscription options.

INDEX INFORMATION  Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

STRENGTHEN DATASETS Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

ANALYZE & INTERPRET PATTERNS Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Redica Systems Enforcement Analytics

Evaluate Your CDMOs

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Compare the inspection history of your CDMO sites.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Compare the enforcement history of your CDMOs.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Monitor compliance at your Clinical Investigator sites.

Enter your email address and someone will contact you shortly to get you started.

Redica Systems Enforcement Analytics

Prepare for inspections of Clinical Investigator sites.

Enter your email address and someone will contact you shortly to provide more Clinical Investigator data about your sites.

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore enforcement trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore observations and trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to run your custom report.

Redica Systems Enforcement Analytics

Compare two companies of your choice.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Download the Special Report

Download your copy of THE FDA INSPECTION LANDSCAPE IN MID-2020 AND A LOOK AT VIRTUAL INSPECTION

In this summary we identify:

  • Trend analysis of FDA inspections through mid-2020
  • Strategies for preparing and hosting virtual inspections
  • New technologies to support remote inspections

Download the Special Report

CDMO Comparison opt-in

In this summary we identify:

FY2018-FY2020 GMP data for Lonza & Catalent

Top GMP primary citations

Top FDA 483 observations

Panel Discussion – Remote Audits

Panel Discussion opt in image

Featuring Panelists:
—Barbara W. Unger, Unger Consulting, Inc.
—Jerry Chapman, Redica Systems
—Stephanie Gaulding, Pharmatech Associates

Who Will Benefit?
This session will be valuable to GMP quality, regulatory, compliance, and management personnel in FDA-regulated industries who want to have a conversation on remote audits and get to know what is going on in the industry.

Turning Failure into Success

Presented on Tuesday, April 27, 2021 by Steve Greer, Executive Coach, Genesis Assist, and former Quality Leader, Procter and Gamble

What you will learn:

  • How to use the Leadership SOS Model to transform quality culture
  • How to strengthen quality systems to eliminate human error
  • How to generate ideas on how to set your organization up for success for shareholders, FDA, and staff
Redica Systems Enforcement Analytics

Get Full Access to Redica Enforcement Analytics

Enter your email address and someone will contact you shortly to answer all of your questions and get you started.

Quality Management Systems for Small Pharma and Biotech Firms

Webinar: QMS for Small Pharma and Biotech Firms

Presented by Fenton Fong, Founder, Managing Director, & Principal at xCellarate

Get instant access to the webinar video and slides.

What you will learn:

  • Common challenges small pharma firms face when developing a QMS
    Recent enforcement trends involving the Quality Unit
    Impact of the COVID-19 pandemic

Download the Special Report

APAC ad

In this summary we identify:

GMP data from FY2017 to FY2020 for the Asia-Pacific region

Top 3 GMP primary and secondary citations

Top 3 483 observations

Download the Special Report

An Analysis Of MHRA’s Latest Annual GMP Inspection Deficiencies Report

In this summary we identify:

  • Data from 2019 UK MHRA Inspections
  • Trends from 2015, 2016, 2018, and 2019 inspections
  • Conclusions drawn from an analysis of drug inspection data

Experience the Power of Redica Systems

Redica Systems

SEARCH Find the inspection records you want by inspector’s name, company name, site, city, country, etc.

WARNING LETTERS Easily search the largest database of FDA Warning Letters by date, company, FDA office, or subject

SITES Quickly assess inspection records including dates and inspectors across all of your sites

INSPECTIONS Complete list of FDA inspections by date, company, category, and country

Get Complete Access to the Redica Systems Platform

Please submit your email address and one of our team members will contact you shortly to answer all of your questions and get you started with the new Enforcement Analytics platform.

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need to prepare for your next inspection.

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Sign up for your FREE account today and get instant access to Enforcement Analytics.

Champion of Change - 3Cs to Success

Webinar: Champion of Change - 3Cs to Success

Presented by Steve Greer on June 23, 2020

What you will learn:

  • The 3C Model to become a champion of change
  • How to identify game-changing habits and the steps to implement them
  • Ways to develop greater purpose-centered leadership
  • How to generate awareness along with actions to create changes in how you think about challenges and change putting you on a path to lead change successfully in your organization
  •  

Download the Special Report

5 GMP Case Studies Report

What You Will Learn from This Report:

The first countrywide import alert issued by FDA

An inadequate deviation investigation

An inadequate product specifications and a product recall

Process validation issues at a CMO

A different perspective on process validation and the culpability of the quality unit

 

Download the Special Report

Quality Week report sidebar

What You Will Learn from This Report:

How a major pharmaceutical company designed a program to train future leaders in quality

An industry-led initiative to advance the state of quality in the pharma industry

A pharma GMP leader’s tips for supporting quality culture within an organization

An update on FDA’s Quality Maturity Model

Impact of the Global Pandemic on Recent Data Integrity and Regulatory Non-compliance Trends

Webinar: Impact of the Global Pandemic on Recent Data Integrity and Regulatory Non-compliance Trends

Presented by Paul Smith, Agilent Technologies on Aug. 26, 2020

What you will learn:

  • Examples of essential laboratory actions to remain compliant during the pandemic
  • Recent data integrity non-compliance findings and trends
  • Essential strategies to find, understand, and leverage regulatory non-compliance data

Past, Present, and Future of Quality Culture

Presented by Regulatory Compliance Associates Distinguished Fellow Susan Schniepp

What you will learn:

  • How the 2014 FDA quality metrics initiative led to greater focus on quality culture
  • New quality culture tools and standards under development by PDA and other organizations
  • Best practices for quality culture, including case studies with lessons learned

Changing Medical Device Regulations

Presented by Redica Systems 

What you will learn:

  • The latest developments regarding the EU MDR
  • Quality Systems requirements for medical devices
  • Regulatory updates affecting medical devices

Download the Special Report

Combination Product Report

What You Will Learn from This Report:

The latest U.S. and European regulatory developments

The impact of smart combination products

How the EU MDR impacts drug-device combination products

Download the Special Report

5 GMP Case Studies Report

What You Will Learn from This Report:

In-depth analysis of the findings

Lessons learned

How companies can avoid similar shortcomings.

Experience the Power of Redica Systems

Redica Systems Expert Jerry Chapman to Present at SQA Annual Meeting

Index Information Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

Strengthen Datasets Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

Analyze & Interpret Patterns Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Download the 510(k) Sample

What You Will Learn from This Sample:

See how a 510(k) submission is structured

Find out what information to include

Review correspondence between sponsor and FDA

Redica Systems Enforcement Analytics

Unlimited Access to Reports and Data

Enter your email address and someone will contact you shortly.

A.I. for Quality and Compliance Teams

August 3 webinar

Presented by Redica Systems Senior GMP Quality Expert Jerry Chapman

What you will learn:

  • A basic understanding of data sources, machine learning, NLP, and A.I. tools
  • Building and applying Expert Models
  • Two case studies, one on sterile manufacturing/503B and one on data integrity
Redica Systems Enforcement Analytics

Upgrade your CDMO management strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Get the scoop on recent data integrity 483 observations!

  • FY 2020 Data Integrity 483 Observations
  • Data Integrity Observations for Human Drugs
  • Observations Falling Under GMP
  •  

Human Factors – Compliance and Applications

June webinar

Presented by Alison Sathe, Founder, Regulatory Mark & Valerie Fenster, Director of Insights and  Human Factors, Kaleidoscope Innovation 

What you will learn:

  • Human factors strategies from simple drug products to complex surgical devices
  • Primary and secondary labeling development and evaluation for usability
  • Human factors activities from product development to post-market
  • International strategies: expectations for human factors in regulatory submissions in international markets

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Let us know who you are and we’ll be in touch to answer all of your questions and get you started.

Redica Systems Enforcement Analytics

Keep up with the latest Regulatory Developments on Clinical Trials

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save your team valuable time when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save time and Resources when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Get immediate access to the news that matters to your sites.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

See how we can help you eliminate yet another spreadsheet.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Stay ahead of changing regulations.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your CDMO monitoring strategy.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Discover the power of the most comprehensive database of 483s in existence.

Our database of over 20,000 483s is retyped and tagged, making it easy to create an Observation Report in seconds.

Eliminate days of work and get your FREE personalized 483 Observation Report.